MASHINIi

PTC Therapeutics, Inc..

PTCT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule drugs targeting post-transcriptional control processes. The company's primary focus is on treatments for rare disorders, including genetic disease...Show More

Ethical Profile

Mixed.

PTC Therapeutics (PTCT.US) presents a mixed ethical profile. The company focuses on developing treatments for rare disorders like Duchenne muscular dystrophy, spinal muscular atrophy, and AADC deficiency, supporting patients through STRIVE Awards and PTC Cares. While an expanded access policy exists for investigational medicines, access is limited, and some gene therapy programs were discontinued. Environmentally, PTC Therapeutics reported total emissions of 45.66 million kg CO2e in 2024, a decrease from 50.43 million kg CO2e in 2023, achieving a DitchCarbon score of 82. However, it lacks SBTi-aligned targets and comprehensive data on renewable energy, water use, and waste. Information on fair pay, ethical sourcing, honest business practices, and animal testing policies is largely unavailable.

Value Scores

Better Health for All-50
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-70
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-50

PTC Therapeutics' core business is focused on the discovery, development, and commercialization of drugs for rare disorders, including genetic diseases, addressing unmet medical needs. This indicates that its entire business is devoted to health improvement, providing exceptional health benefits. The company generally does not offer expanded access to investigational medicines, prioritizing clinical trials for regulatory approval, and its policy is subject to change without notice.

1
PTC Therapeutics also reduced its workforce due to pipeline prioritization.
2
While the company supports patient advocacy organizations through its STRIVE Awards, including a grant to hire professionals for a power soccer program in Brazil, and a grant for a digital health app in Australia to help patients manage their health, these are limited initiatives.
3
The company's grant program supports medical education, charitable donations, and patient advocacy, but no quantitative data on funding or impact is provided.
4

Fair Money & Economic Opportunity

0

The provided articles do not contain any information regarding PTC Therapeutics' involvement in financial services, lending, or economic opportunity initiatives. All articles either resulted in a 404 error or focused on unrelated topics such as biotech investment landscapes or drug approvals. Therefore, no specific, concrete data points could be extracted from the evidence to assess the company against any of the 'Fair Money & Economic Opportunity' KPIs.

Fair Pay & Worker Respect

0

No evidence available to assess PTC Therapeutics, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No evidence available to assess PTC Therapeutics, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess PTC Therapeutics, Inc. on Honest & Fair Business.

Kind to Animals

-40

The company conducts animal testing in the discovery, development, and commercialization of some of its therapeutics, including pre-clinical trials using animal models.

1
While the article does not explicitly state 'no formal policy,' it indicates that animal testing is a routine part of their operations without mentioning any restrictions, reduction goals, or prohibitions. This suggests a policy that permits routine testing without clear limitations or a vague policy that allows such practices.

No War, No Weapons

0

No evidence available to assess PTC Therapeutics, Inc. on No War, No Weapons.

Planet-Friendly Business

-70

PTC Therapeutics has no SBTi commitment

1
and no SBTi-aligned targets are mentioned in its 2023 Corporate Sustainability Report.
2
The company has not provided scope 1, 2, or 3 emissions data,
3
nor a net-zero target year.
4
While the company engages in tree planting, with 100 trees planted in Switzerland for two consecutive years
5
and a total of 2,110 trees planted across the U.S., LATAM, EMEA/APAC in 2023,
6
these are considered minimal pilot projects without a portfolio-wide biodiversity strategy. The 2023 Corporate Sustainability Report states no environmental compliance violations.
7
There is no evidence of programs addressing disproportionate climate impacts on vulnerable communities,
8
support for workers transitioning from high-carbon to low-carbon economies,
9
or investment in climate adaptation for vulnerable communities.
10

Respect for Cultures & Communities

0

No evidence available to assess PTC Therapeutics, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

No evidence available to assess PTC Therapeutics, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No specific, quantitative, or factual evidence was found in the provided articles for any of the Zero Waste & Sustainable Products KPIs for PTC Therapeutics, Inc. (PTCT.US). Several articles discuss general sustainability concepts or are related to a different company (PTC, a software company) rather than the biopharmaceutical company PTCT.US.

1
Other articles about PTCT.US's sustainability efforts or corporate responsibility reports explicitly state that no relevant data for these KPIs is provided.
2

Own PTC Therapeutics, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.